A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Anna Czopek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. Hauptthemen laut MEDLINE: Antidepressive Agents, Receptors, Serotonin, Anti-Anxiety Agents, Serotonin Antagonists. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Science Center Poland.
Abstract (Originalsprache)
The aim of this study was to characterize the pharmacological profile of a newly synthesized compound 5 ( R,S) −1‐(5‐{4‐[(1,1'‐biphenyl)‐2‐yl]piperazin‐1‐yl}pentyl)−3',4'‐dihydro‐2' H ‐spiro[imidazolidine‐4,1'‐naphthalene]‐2,5‐dione, designed as a dual‐acting ligand targeting the serotonin 5‐HT 7 receptor and voltage‐gated sodium channels. In vitro studies demonstrated that compound 5 exhibits high affinity for the 5‐HT 7 receptor (K i = 19 nM), comparable to the reference ligand LP‐211, and potent inhibition of sodium channels, markedly stronger than that of phenytoin. Functional assays confirmed that compound 5 acts as a 5‐HT 7 receptor antagonist (K b = 87 nM) with no detectable agonist activity. In addition, the compound showed negligible affinity for the serotonin transporter (SERT), indicating a favorable selectivity profile. Molecular docking studies revealed a stable binding mode of compound 5 within the orthosteric site of the 5‐HT 7 receptor, consistent with known GPCR interaction patterns. Modifications to compound 5 improved its safety by reducing hepatocytotoxicity in HepG2 cells. In vivo behavioral experiments demonstrated significant antidepressant‐like effects in the forced swim test and anxiolytic‐like effects in the four‐plate test in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
- Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
ORCID-Profile: Anna Czopek, Katarzyna Wójcik-Pszczoła, Michał Sapa, Krzysztof Kamiński, Grzegorz Satała, Andrzej J Bojarski, Kinga Sałat
Förderung
- National Science Center Poland
Zitieren
APA
Czopek, A., Wójcik-Pszczoła, K., Koczurkiewicz-Adamczyk, P., Sapa, M., Kamiński, K., Satała, G., Bojarski, A. J., Siwek, A., Wolak, M., & Sałat, K. (2026). A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70366
Vancouver
Czopek A, Wójcik-Pszczoła K, Koczurkiewicz-Adamczyk P, Sapa M, Kamiński K, Satała G, et al. A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70366
BibTeX
@article{Czopek2026,
author = {Czopek, Anna and Wójcik-Pszczoła, Katarzyna and Koczurkiewicz-Adamczyk, Paulina and Sapa, Michał and Kamiński, Krzysztof and Satała, Grzegorz and Bojarski, Andrzej J and Siwek, Agata and Wolak, Małgorzata and Sałat, Kinga},
title = {A Dual 5‐HT 7 Receptor Antagonist and Sodium Channel Inhibitor With Antidepressant‐ and Anxiolytic‐Like Activity and Reduced Hepatotoxicity},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70366}
}
EUVIMED